Invention Grant
- Patent Title: Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease
-
Application No.: US16368992Application Date: 2019-03-29
-
Publication No.: US10675272B2Publication Date: 2020-06-09
- Inventor: Samit Hirawat , Langdon Miller
- Applicant: PTC Therapeutics, Inc.
- Applicant Address: US NJ South Plainfield
- Assignee: PTC Therapeutics, Inc.
- Current Assignee: PTC Therapeutics, Inc.
- Current Assignee Address: US NJ South Plainfield
- Agency: Jones Day
- Main IPC: A61K31/4245
- IPC: A61K31/4245 ; A61K9/14 ; A61K9/00
Abstract:
The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
Public/Granted literature
- US20190224173A1 COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE Public/Granted day:2019-07-25
Information query
